Get the Stockscreener App
1.32
3.13%
0.04
After Hours:
1.34
0.02
+1.52%
Dare Bioscience Inc stock is traded at $1.32, with a volume of 168.00K.
It is up +3.13% in the last 24 hours and down -36.84% over the past month.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
See More
Previous Close:
$1.28
Open:
$1.28
24h Volume:
168.00K
Relative Volume:
0.42
Market Cap:
$19.77M
Revenue:
$1.16M
Net Income/Loss:
$-12.02M
P/E Ratio:
-1.2716
EPS:
-1.0381
Net Cash Flow:
$-10.16M
1W Performance:
-1.49%
1M Performance:
-36.84%
6M Performance:
-32.99%
1Y Performance:
-48.64%
1-Day Range:
$1.28
$1.35
1-Week Range:
$1.16
$1.36
52-Week Range:
$1.16
$3.78
Dare Bioscience Inc Stock (DARE) Company Profile
Name
Dare Bioscience Inc
Sector
Industry
Phone
858-926-7655
Address
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
1.32 | 19.17M | 1.16M | -12.02M | -10.16M | -1.0381 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Dare Bioscience Inc Stock (DARE) Latest News
Dare Bioscience Inc (DARE) Income Statement - TradingKey
Dare Bioscience Inc (DARE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dare Bioscience Inc (DARE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Dare Bioscience Market Sentiment - Benzinga España
DARE|Dare Bioscience Inc|Price:1.280|Chg%:+0.020 - TradingKey
Dare Bioscience Inc (DARE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Daré Bioscience Releases New Investor Corporate Presentation - TipRanks
Dare Bioscience Inc (DARE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - simplywall.st
Daré Bioscience launches virtual bus tour webin... - Pluang
Daré Bioscience Launches “Across the U.S.” Virtual Bus Tour Webinar Series for Investors - Quiver Quantitative
Daré Bioscience Launches Nationwide Virtual Bus Tour - GlobeNewswire
Daré Bioscience Files 8-K Notice of Delisting or Failure to Satisfy Nasdaq Listing Requirements – July 2026 - Minichart
Daré Bioscience Faces Nasdaq Listing Compliance Challenges - TipRanks
Dare Bioscience Received Notice of Delisting - TradingView
Daré Bioscience Advances DARE-HPV Trial, Raising New Questions for HPV Treatment Investors - TipRanks
Daré Bioscience at Virtual Investor Closing Bell: shift to sales By Investing.com - Investing.com Canada
DARE: Commercial launches and clinical milestones in women's health drive growth and value through 2027 - TradingView
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025 - 富途牛牛
Daré Bioscience Updates Investors With New Presentation - TipRanks
[8-K] Dare Bioscience, Inc. Reports Material Event - Stock Titan
Dare Bioscience Company Profile & Introduction - Moomoo
Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event - The Manila Times
Daré Bioscience CEO to discuss FloraSync launch, Q&A July 14 - Stock Titan
Price to sales forward of Dare Bioscience, Inc. – NASDAQ:DARE - TradingView
DARE Technical Analysis & Stock Price Forecast - Intellectia AI
Daré Bioscience launches prescription-free vaginal probiotic capsule for microbiome support - Contemporary OB/GYN
Price to earnings forward of Dare Bioscience, Inc. – NASDAQ:DARE - TradingView
Dare Bioscience (DARE) director receives 23,696 RSUs in lieu of cash pay - Stock Titan
Dare Bioscience (DARE) director awarded 30,805 RSUs as board compensation - Stock Titan
Dare Bioscience (DARE) grants 38,862 RSUs to board director - Stock Titan
Dare Bioscience (DARE) director receives 26,540 RSUs in lieu of cash fees - Stock Titan
Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform - The Manila Times
Daré Bioscience Launches Flora Sync LF5 Vaginal Probiotic, Marks First Direct Consumer Product Revenue - Quiver Quantitative
Daré Bioscience’s vaginal probiotic is now for sale online - Stock Titan
Daré Bioscience, Inc.(NasdaqCM: DARE) added to Russell 3000E Growth Benchmark - marketscreener.com
Daré Bioscience, Inc.(NasdaqCM: DARE) added to Russell 3000E Index - marketscreener.com
Daré Bioscience, Inc.(NasdaqCM: DARE) added to Russell Microcap Index - marketscreener.com
Daré Bioscience, Inc.(NasdaqCM:DARE) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Dare Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5 in Virtual Investor What This Means Segment - marketscreener.com
Dare Bioscience, Inc. Actuals & Estimates (NASDAQ:DARE) - TradingView
DARE Forecast — Price Target — Prediction for 2027 - TradingView
Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor 'What This Means” Segment - The Manila Times
Daré Bioscience Highlights Revenue Opportunity as CEO - GlobeNewswire
Daré Bioscience, Inc. (DARE) Presents at BIO International Convention 2026Slideshow (NASDAQ:DARE) 2026-06-23 - Seeking Alpha
Daré Bioscience Issues New Corporate Investor Presentation - TipRanks
Form 8K Dare Bioscience Inc For: 22 June By Investing.com - Investing.com South Africa
Dare Bioscience (DARE) unveils June 22, 2026 corporate investor presentation - Stock Titan
Daré Bioscience to Present Corporate Strategy and Participate in Multiple Speaking Engagements at BIO International Convention 2026 - Quiver Quantitative
Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026 - GlobeNewswire
Dare Bioscience Inc Stock (DARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):